Product Description
Description: Torque’s Glimtor PM2 Tablets contains Glimepiride, a sulphonylurea antihyperglycaemic agent acts mainly by stimulating insulin release from pancreatic beta cells, Pioglitazone, a thiazolidinedione antihyperglycaemic agent acts by a reduction of insulin resistance and Metformin, a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.
Pharmaceutical Dosage Form: Tablet
Route of Administration: Oral
Composition:
Each uncoated bilayered tablet contains:
Glimepiride IP 2 mg
Pioglitazone Hydrochloride IP
Eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP 500 mg
(as extended release form)
Excipients q.s.
Mechanism of Action: Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta-cells. It binds to the sulphonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Indications: Torque’s Glimtor PM2 is indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.
Dosage: As directed by the physician.
Storage: Store protected from moisture, at a temperature not exceeding 25ºC.
Presentation: 10 x 2 x 15
Side effects: The following adverse reactions may occur:
Lactic Acidosis
Taste Disturbance
Nausea, Vomiting, Diarrhoea, Abdominal Pain, Flatulence, Loss of Appetite
Upper respiratory tract infection
Anaemia
Hypo-Glycaemia
Hypo-Aesthesia
Headache, Dizziness
Arthralgia, Back Pain
Haematuria
Erectile Dysfunction
Contraindications:
Torque’s Glimtor PM2 is contraindicated in patients with:
Known hypersensitivity to metformin, glimepiride, pioglitazone or any of the components of this product.
Severe renal impairment
Acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis
Diabetic pre-coma
Patients with established NYHA class III or IV heart failure
Acute or chronic disease which may cause tissue hypoxia such as cardiac or respiratory
failure, recent myocardial infarction, shock
Hepatic insufficiency, acute alcohol intoxication, alcoholism
Acute conditions with the potential to alter renal function such as:
– Dehydration
– Severe infection
– Shock
– Intravascular administration of iodinated contrast agents
Lactation
Drug Interactions:
Alcohol
NSAIDs
ACE Inhibitors
Angiotensin II Receptor Antagonists
Diuretics
Verapamil
Rifampicin
Cimetidine, Dolutegravir, Ranolazine, Trimethoprime,
Isavuconazole, Fluconazole
Vandetanib, Crizotinib, Olaparib
Thyroid Stimulating Agents, Glucocorticoids
Anabolic Steroids and Male Sex Hormones
Gemfibrozil
